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Abstract— We describe a case of reversible Brugada Syndrome 
in a patient on Clozapine for schizophrenia, highlighting the risk 
of antipsychotics causing a variety of phenotypic expressions of 
predisposing sodium channelopathy.  
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I.  CLINICAL CASE REPORT 
Our patient was a 49 year old male with a background of 
schizophrenia diagnosed in February 2004. His condition was 
poorly controlled on Zuclopenthixol injections commenced in 
May 2006. He was subsequently commenced on Clozapine in 
2009 with improvement in schizophrenia control. However, an 
electrocardiogram (ECG) performed post commencement of 
Clozapine revealed an incomplete right bundle branch block 
and ST elevations in V1 to V3, suggestive of Brugada 
Syndrome. This raised the concern of the risk of sudden 
cardiac death whilst on Clozapine. 
Clozapine was withheld and a thorough cardiac 
assessment was performed. The patient reported no previous 
personal history of angina, palpitations, pre-syncope or 
syncope. There was no known family history of sudden 
cardiac death. His other past medical history included 
hypertension and hypertension-related ventricular 
hypertrophy. 
His medications included Chlorpromazine 
hydrochloride 200mg nocte, Chlopromazine hydrochloride 
50mg nocte PRN, Enalapril/Hydrochlorothiazide 20mg/6mg 
daily, Budesonide/Eformoterol 400/12 micrograms 2 puffs 
BD and Simvastatin 40mg daily. 
An echocardiogram performed on 31st March 2009 
showed normal diameters of all 4 heart chambers, concentric 
left ventricular hypertrophy with no signs of heart failure or 
myocarditis. There was no change to his previous 
echocardiogram. A troponin was sent which was negative 
hence making myocarditis unlikely. Holter monitoring was 
performed which revealed sinus rhythm with no significant 
arrhythmias detected. 
Novartis Cardiologist was contacted and it was thought 
that Clozapine was responsible for a Brugada Syndrome 
pattern on the patient’s ECG. Clozapine can interfere with 
sodium channels and Brugada Syndrome ECG changes can be 
brought out in a patient so predisposed. The consensus opinion 
was for Clozapine to be ceased. Should rechallenge with 
Clozapine be required for control of schizophrenia symptoms, 
this should occur in an inpatient setting with daily ECG 
monitoring. 
Electrophysiological studies would be indicated 
particularly if there was a family history of premature sudden 
death. Clozapine therapy would be contraindicated should 
recurrent Brugada Syndrome-like changes develop. 
 
Figure 1. ECG prior to Clozapine 
 
 
Figure 2. ECG post Clozapine 
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II. DISCUSSION 
Schizophrenia has a lifetime prevalence of 0.55% and an 
annual incidence of about 0.015% [1]. The disease can be a 
distressing and debilitating condition for the sufferer.  
Clozapine is a useful atypical antipsychotic for 
schizophrenia symptoms that are refractory and has been 
shown to reduce suicide rates in patients [2]. Commonly 
described cardiovascular side-effects of Clozapine include 
myocarditis, with cardiomyopathy and pericarditis also being 
described [2]. Whilst existing literature have alluded to the 
potential that sodium channel blocking agents like Clozapine 
can induce Brugada syndrome [3], there have been no case 
reports published to date on actual clinical cases. 
Brugada Syndrome is inherited as an autosomal 
dominant condition with incomplete penetrance [4] but can 
also be associated with use of tricyclic antidepressants and 
neuroleptics [5]. Brugada Syndrome can cause ventricular 
arrhythmias like ventricular tachycardia and fibrillation in 
structurally normal hearts, leading to sudden cardiac death in 
about 20% of untreated patients [5]. 
The point prevalence of the Brugada Syndrome ECG 
pattern in the healthy population has been estimated at 1–5 per 
10,000 people throughout the world [6]. 
Drugs described with the potential to cause Brugada 
Syndrome include Lithium, and possibly other mood 
stabilizers that block sodium channels (e.g., carbamazepine, 
oxcarbazepine, valproate, lamotrigine) [7].  Other psychiatric 
medications such as tricyclic antidepressants (e.g., 
amitriptyline, desipramine), clozapine, and selective serotonin 
reuptake inhibitors (e.g., fluoxetine), also affect the activity 
and function of cardiac sodium channels [7]. Hence, these 
medications may also increase the risk of developing 
symptomatic Brugada Syndrome [7]. 
Mutations in the SCN5A gene with resultant gain-of-
function can cause Long QT type 3 Syndrome through 
overactive cardiac sodium channels leaking sodium and 
causing prolongation of the action potential [8]. Loss-of-
function mutations in the SCN5A gene can cause Brugada 
Syndrome through underactive sodium channels [8].  Both 
clinical conditions tend to present with nocturnal sudden 
cardiac death, and families exist where the same genetic 
mutation can result in both of these conditions being present 
in different family members [8]. 
Several mechanisms through which Clozapine induces 
Brugada Syndrome can be postulated. Clozapine can induce a 
sodium channelopathy [3], which is the pathogenesis of 
Brugada Syndrome. Sodium channelopathy selectively 
affecting the epicardium results in a transmural voltage 
discrepancy between the epicardium and the endocardium [4]. 
There is inhomogeneous repolarization in different areas 
of the right ventricular epicardium leading to phase 2 re-entry 
[4]. This in turn gives rise to closely coupled extrasystoles 
which can trigger ventricular tachycardia or fibrillation [4]. 
Other factors that can affect the size of the voltage discrepancy 
include the testosterone effect of the male gender [4]. The 
Brugada Syndrome phenotype is more commonly observed in 
males than females due to the presence of more prominent 
transient outward current channels in males than females [5]. 
In the case of our patient, whilst Brugada Syndrome was 
thought to be a direct effect of Clozapine use, it was also 
postulated that Clozapine use could have unraveled the 
Brugada Syndrome ECG phenotype in the patient who was 
genetically predisposed. Lithium causing phenotypic 
expression of Brugada syndrome has been described in current 
literature [7]. Certainly, in another case of a 42 year old man 
with syncope on Lithium, provocation testing with ajmaline in 
the patient who was taken off Lithium demonstrated ST 
segment elevations in the anterior chest leads [7]. Whilst the 
patient denied personal or family history of sudden death or 
syncope, ajmaline testing clearly unraveled predisposing 
sodium channelopathy [7].  
At the molecular level, it has been proposed that the 
cardiac voltage-gated sodium channel (Nav1.5) may be part of 
a complex of proteins that are regulated by anchoring proteins, 
modifying enzymes and modulating proteins [9]. Phenotypic 
SCN5A disease has been found to be related to mutations in 
genes encoding these regulatory proteins [9]. Consideration 
should be given to the pathogenic potential of mutations in 
these regulatory proteins in the context of drug-induced 
Brugada Syndrome as well. It has also been postulated that 
various Nav1.5 channel complexes consists of different 
proteins and are regulated differently depending on their 
location within the cell membrane compartments [9]. This 
could explain why a certain medication can result in 2 different 
phenotypes (Long QT or Brugada Syndrome) depending on 
the concentration, distribution and location of various Nav1.5 
channels within the cell. 
A subgroup of familial sudden cardiac death syndrome 
has been identified in which a Brugada Syndrome phenotype 
is seen in combination with a short QT interval (QT interval 
(corrected) ≤ 360 ms) [5]. In these patients, gene mutations 
affecting the calcium channel have been found to be the 
underlying cause [5]. These include loss-of-function missense 
mutations in CACNA1C (A39V and G490R) gene and 
CACNB2 (S481L) gene encoding the a1-subunits and b2b-
subunits of the L-type calcium channel [5]. This development 
may pave the way for the discovery of other ion 
channelopathies apart from Nav1.5 that might contribute to the 
Brugada Syndrome phenotype and its various subtypes. 
Indeed, it can be postulated that the interaction of psychotropic 
drugs with various ion channels apart from Nav1.5 may even 
help explain drug-induced Brugada Syndrome phenotype seen 
in individual cases. 
In conclusion, it is important to be aware of the typical 
signs of Brugada Syndrome in psychiatric patients being 
treated with psychotropic medications. Baseline ECG 
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monitoring in these patients is paramount to pre-empting 
serious cardiac sequelae. Just as the same genetic mutation in 
the SCN5A gene (or Nav1.5 regulatory proteins genes) can 
result in either Long QT Syndrome or Brugada Syndrome in 
different individuals [9], it appears that Clozapine can induce 
either Long QT Syndrome or Brugada Syndrome in different 
patients on this medication. Whilst focus has been placed on 
the role of sodium channelopathy in drug-induced Brugada 
Syndrome, new paths of discovery could involve other ion 
channelopathies and their role in the pathophysiology of 
Brugada Syndrome subtypes.  Whilst research literature exists 
on the observed effect of Clozapine-induced QT prolongation 
[10], more research needs to be done on the prevalence, 
pathogenesis and molecular pathology of Clozapine-induced 
Brugada Syndrome.   
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